Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle

This article was originally published in The Tan Sheet

Executive Summary

Jose Saavedra, MD, named medical and scientific director, nutrition division. Saavedra joins Nestle from Johns Hopkins University, where he specialized in pediatric gastroenterology and the use of probiotics in children. Glendale, Calif.-based Nestle markets the probiotic LC1, a powder that can be added to foods and beverages (1"The Tan Sheet" March 6, p. 4). In an article in the Sept. 20 Journal of the American Medical Association, Saavedra discusses probiotics, noting Lactobacillus can "decrease the duration and severity of episodes of acute diarrhea"

You may also be interested in...



Nestle LC1 Probiotic Supplement Launching With Direct Mail, Print Support

Nestle USA is introducing its first dietary supplement product, Nestle LC1, with print ads and direct mail support expected to break the week of March 5.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel